![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Tokai Ends Cancer Trial After Phase 3 Shows Meager Results
Tokai Ends Cancer Trial After Phase 3 Shows Meager Results
Tokai Pharmaceuticals is stopping work on a Phase 3 trial for a metastatic cancer candidate after getting negative feedback from a review group.
The company called a halt to the work on candidate drug galeterone after a data monitoring committee concluded that the head-to-head trial is unlikely to meet its primary endpoint of improved radiographic progression-free survival versus the drug enzalutamide.
The company says it will continue to allow patients to receive the drug after consulting with their physicians and study investigators.
Upcoming Events
-
21Oct